Aldosterone antagonism: An emerging strategy for effective blood pressure lowering

Current Hypertension Reports

Volumn 7, Issue 3, 2005, Pages 186-192

  Pratt Ubunama, Monique N ^a   Nishizaka, Mari K ^a   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROCHLOROTHIAZIDE; LOSARTAN; POTASSIUM; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; LIBIDO DISORDER; MENSTRUAL IRREGULARITY; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEXUAL DYSFUNCTION;

EID: 21244461574     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0008-1     Document Type: Article

References (26)

1. Conn JW: Presidential address. Part I: painting background; Part II: primary aldosteronism - a new clinical syndrome. J Lab Clin Med 1955, 45:3-17.
2. Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-318.
3. Mosso L, Carvajal C, Gonzalez A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161-165.
4. Lim Po, Dow E, Brennan G, et al.: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000, 12:311-314.
5. Fardella CE, Mosso L, Gomez-Sanchez C, et al.: Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863-1867.
6. Kreeze A, Okalova D, Vanuga P, et al.: Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients. Vintr Lek 1999, 45:17-21.
7. Calhoun DA, Nishizaka MK, Zaman MA, et al.: High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
8. Galley BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699-705.
9. Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin-status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217-2226.
10. Conn JW, Cohen EL, Rovner DF, et al.: Normokalemic primary aldosteronism: a detectable cause of curable "essential" hypertension. JAMA 1965, 193:200-206.
11. Vasan RS, Evans JC, Larson MG, et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004, 351:33-41.
12. Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
13. Weinberger MH, Roniker B, Krause SL, et al.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709-716.
14. White WB, Carr AA, Krausse S, et al.: Assessment of novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003, 92:38-42.
15. White B, Duprez D, St Hillaire R, et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003, 41:1021-1026.
16. Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148-1155.
17. Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117-123.
18. Ouzan J, Perault C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333-339.
19. Lim PO, Jung RT, MacDonald TM: Raised aldosterone to renin predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999, 48:756-760.
20. Schepkens H, Vanholder R, Billiouw J, et al.: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001, 110:438-441.
21. Ghose RP, Hall PM, Bravo EL: Medical management of aldosterone-producing adenomas. Ann Intern Med 1999, 131:105-108.
22. Kaplan NM: The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004, 22:863-869.
23. Spence JD: The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004, 22:2038-2039.
24. Krishnan PH, MacDonald T: The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004, 22:2039-2040.
25. Goodfriend TL, Egan BM, Kelley DE: Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999, 60:401-405.
26. Calhoun DA, Nishizaka MK, Zaman MA, et al.: Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125:112-117.